专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070178452A1 Method for analyzing a nucleic acid 审中-公开
标题翻译：分析核酸的方法
公开(公告)号：US20070178452A1
公开(公告)日：2007-08-02
申请号：US10277951
申请日：2002-10-21
申请人： Pascal Bouffard , John Herrmann , Chunli Huang , Michael Jeffers , Jingfang Ju , Luca Rastelli , Juliette Shimkets , Jan Simons , Bruce Taillon
发明人： Pascal Bouffard , John Herrmann , Chunli Huang , Michael Jeffers , Jingfang Ju , Luca Rastelli , Juliette Shimkets , Jan Simons , Bruce Taillon
IPC分类号： C12Q1/68 , G06F19/00
CPC分类号： C12N15/1096 , C12Q2600/158 , G16B30/00
摘要： Disclosed is a method in which DNA sequences derived from microsome-associated mRNA sequences in a mixed sample or in an arrayed single sequence clone can be determined and classified without sequencing. The methods make use of information on the presence of carefully chosen target subsequences, typically of length from 4 to 8 base pairs, and preferably the length between target subsequences in a sample DNA sequence together with DNA sequence databases containing lists of sequences likely to be present in the sample to determine a sample sequence. The preferred method uses restriction endonucleases to recognize target subsequences and cut the sample sequence. Then carefully chosen recognition moieties are ligated to the cut fragments, the fragments amplified, and the experimental observation made. Polymerase chain reaction (PCR) is the preferred method of amplification. Another embodiment of the invention uses information on the presence or absence of carefully chosen target subsequences in a single sequence clone together with DNA sequence databases to determine the clone sequence. Computer implemented methods are provided to analyze the experimental results and to determine the sample sequences in question and to carefully choose target subsequences in order that experiments yield a maximum amount of information
摘要翻译：公开了可以确定和分类来自混合样品或排列单序列克隆中的微粒体相关mRNA序列的DNA序列而不进行测序的方法。这些方法利用关于精确选择的目标子序列的存在的信息，通常长度为4至8个碱基对，优选样品DNA序列中目标子序列之间的长度以及含有可能存在的序列的DNA序列数据库在样品中确定样品序列。优选的方法是使用限制性核酸内切酶识别目标子序列并切割样品序列。然后仔细选择识别部分连接到切割片段，扩增片段，并进行实验观察。聚合酶链反应（PCR）是优选的扩增方法。本发明的另一个实施方案使用关于在单个序列克隆中与DNA序列数据库一起存在或不存在仔细选择的目标子序列的信息来确定克隆序列。提供计算机实现的方法来分析实验结果并确定所讨论的样本序列，并仔细选择目标子序列，以便实验产生最大量的信息

2. 发明授权

US08927207B2 miRNAs as therapeutic targets in cancer 有权
标题翻译： miRNA作为癌症治疗靶点
公开(公告)号：US08927207B2
公开(公告)日：2015-01-06
申请号：US12996249
申请日：2009-06-05
申请人： Jingfang Ju , Bo Song , Yuan Wang
发明人： Jingfang Ju , Bo Song , Yuan Wang
IPC分类号： C12Q1/68 , C12N15/113
CPC分类号： C12N15/1137 , A61K31/7088 , A61K45/06 , C12N15/113 , C12N15/1135 , C12N2310/113 , C12N2310/14 , C12N2320/31 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178
摘要： MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3′ untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
摘要翻译：微RNA（miRNA）是一类非编码小RNA分子，通过与其靶mRNA的3'非翻译区（UTR）相互作用，在转录后水平调节基因表达。本发明涉及miR-192和miR-215的应用。这两种miRNA通过p53-miRNA电路影响细胞增殖，并与二氢叶酸还原酶（DHFR）和胸苷酸合酶（TS）相互作用。特别地，这些miRNA的上调减少细胞增殖。本发明涉及这一发现。例如，抑制miR-192和/或miR-215使肿瘤或具有肿瘤的受试者对化学治疗剂敏感。此外，测量miR-192和/或miR-215的水平提供了关于肿瘤或受试者是否将对化学治疗剂作出反应的信息。因此，本发明涉及与miR-192和miR-215的表达的鉴定，表征和调节相关的组合物和方法。

3. 发明申请

US20110166201A1 MIRNAS AS THERAPEUTIC TARGETS IN CANCER 有权
标题翻译： MIRNAS作为癌症中的治疗目标
公开(公告)号：US20110166201A1
公开(公告)日：2011-07-07
申请号：US12996249
申请日：2009-06-05
申请人： Jingfang Ju , Bo Song , Yuan Wang
发明人： Jingfang Ju , Bo Song , Yuan Wang
IPC分类号： A61K31/7052 , C12N5/00 , C12Q1/68 , C07H21/00 , A61P35/00
CPC分类号： C12N15/1137 , A61K31/7088 , A61K45/06 , C12N15/113 , C12N15/1135 , C12N2310/113 , C12N2310/14 , C12N2320/31 , C12Q1/6886 , C12Q2600/136 , C12Q2600/178
摘要： MicroRNAs (miRNAs) are a class of non-coding small RNA molecules that regulate gene expression at the post-transcriptional level by interacting with 3′ untranslated regions (UTRs) of their target mRNAs. The invention relates to the application of miR-192 and miR-215. Both of these miRNAs impact cellular proliferation through the p53-miRNA circuit, and interact with dihydrofolate reductase (DHFR) and thymidylate synthase (TS). Particularly, upregulation of these miRNAs reduces cellular proliferation. The invention relates to this discovery. For example, inhibiting miR-192 and/or miR-215 sensitizes a neoplasm or a subject with a neoplasm to chemotherapeutic agents. Furthermore, measuring the levels of miR-192 and/or miR-215 provides one with information regarding whether the neoplasm or subject will respond to chemotherapeutic agents. Accordingly, the invention relates to composition and methods relating to the identification, characterization and modulation of the expression of miR-192 and miR-215.
摘要翻译：微RNA（miRNA）是一类非编码小RNA分子，通过与其靶mRNA的3'非翻译区（UTR）相互作用，在转录后水平调节基因表达。本发明涉及miR-192和miR-215的应用。这两种miRNA通过p53-miRNA电路影响细胞增殖，并与二氢叶酸还原酶（DHFR）和胸苷酸合酶（TS）相互作用。特别地，这些miRNA的上调减少细胞增殖。本发明涉及这一发现。例如，抑制miR-192和/或miR-215使肿瘤或具有肿瘤的受试者对化学治疗剂敏感。此外，测量miR-192和/或miR-215的水平提供了关于肿瘤或受试者是否将对化学治疗剂作出反应的信息。因此，本发明涉及与miR-192和miR-215的表达的鉴定，表征和调节相关的组合物和方法。

4. 发明申请

US20100203513A1 MICRORNA AS BIOMARKER IN CANCER 失效
标题翻译： MICRORNA作为生物标记在癌症
公开(公告)号：US20100203513A1
公开(公告)日：2010-08-12
申请号：US12513007
申请日：2007-10-30
申请人： Jingfang Ju , Yaguang Xi , Nakajima Go
发明人： Jingfang Ju , Yaguang Xi , Nakajima Go
IPC分类号： C12Q1/68 , C07H21/00
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/178
摘要： The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.
摘要翻译：本发明涉及与关于癌症的某些信息相关的某些微小RNA的发现。本发明的微小RNA选自hsa-miR-15b，hsa-miR-181b，hsa-miR-191，hsa-miR-200c和hsa-let-7g。如果这些microRNA的表达增加，则这些microRNA的表达增加是癌症的诊断，癌症的特征，预测对癌症治疗的预期响应和/或预测患者的预期存活。该发现的实施方案包括方法，组合物，试剂盒和分离的核酸。

5. 发明授权

US08343719B2 Microrna as biomarker in cancer 失效
标题翻译： Microrna作为癌症中的生物标志物
公开(公告)号：US08343719B2
公开(公告)日：2013-01-01
申请号：US12513007
申请日：2007-10-30
申请人： Jingfang Ju , Yaguang Xi , Nakajima Go
发明人： Jingfang Ju , Yaguang Xi , Nakajima Go
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/178
摘要： The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid.
摘要翻译：本发明涉及与关于癌症的某些信息相关的某些微小RNA的发现。本发明的微小RNA选自hsa-miR-15b，hsa-miR-181b，hsa-miR-191，hsa-miR-200c和hsa-let-7g。如果这些microRNA的表达增加，则这些微小RNA的表达增加是对癌症的诊断，表征癌症，预测对癌症治疗的预期响应和/或预测患者的预期存活。该发现的实施方案包括方法，组合物，试剂盒和分离的核酸。

6. 发明申请

US20120087992A1 miRNAS AS THERAPEUTIC TARGETS IN CANCER 审中-公开
标题翻译： miRNA作为癌症中的治疗目标
公开(公告)号：US20120087992A1
公开(公告)日：2012-04-12
申请号：US13257836
申请日：2010-03-22
申请人： Jingfang Ju , Yuan Wang , Bo Song
发明人： Jingfang Ju , Yuan Wang , Bo Song
IPC分类号： A61K31/7088 , A61K33/24 , A61N5/00 , C07H21/02 , C12Q1/68 , C12N5/00 , A61K31/704
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K45/06 , C12Q1/6809 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , C12Q2600/178 , A61K2300/00 , C12Q2525/207
摘要： Methods for modulating expression of a component of a cell, comprising contacting the cell with a nucleic acid comprising an miR-140 nucleic acid sequence in an amount sufficient to modulate the cellular component are provided. Overexpression of miR-140 inhibits cell proliferation in both U-2 OS (wt-p53) and HCT 116 (wt-p53) cell lines. Cells transfected with miR-140 are more resistant to chemotherapeutic agent methotrexate, mi-140 expression is related to HDAC4 protein expression. The claimed methods reduce the protein expression level of HDAC4 without degrading the target mRNA.
摘要翻译：提供了调节细胞成分表达的方法，包括使细胞与含有足以调节细胞成分的量的miR-140核酸序列的核酸接触。 miR-140的过表达抑制U-2 OS（wt-p53）和HCT 116（wt-p53）细胞系中的细胞增殖。用miR-140转染的细胞对化学治疗剂甲氨蝶呤更具抗性，mi-140表达与HDAC4蛋白表达有关。所要求的方法降低HDAC4的蛋白质表达水平，而不降解靶mRNA。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式